SG10201708166SA - Tert-Butyl N-[2-{4-[6-Amino-5-(2,4-Difluorobenzoyl)-2-Oxopyridin-1(2H)-yl]-3,5-Difluorophenyl}Ethyl]-L-Alaninate Or A Salt, Hydrate Or Solvate Thereof - Google Patents
Tert-Butyl N-[2-{4-[6-Amino-5-(2,4-Difluorobenzoyl)-2-Oxopyridin-1(2H)-yl]-3,5-Difluorophenyl}Ethyl]-L-Alaninate Or A Salt, Hydrate Or Solvate ThereofInfo
- Publication number
- SG10201708166SA SG10201708166SA SG10201708166SA SG10201708166SA SG10201708166SA SG 10201708166S A SG10201708166S A SG 10201708166SA SG 10201708166S A SG10201708166S A SG 10201708166SA SG 10201708166S A SG10201708166S A SG 10201708166SA SG 10201708166S A SG10201708166S A SG 10201708166SA
- Authority
- SG
- Singapore
- Prior art keywords
- oxopyridin
- difluorobenzoyl
- alaninate
- difluorophenyl
- solvate
- Prior art date
Links
- 150000003839 salts Chemical class 0.000 title 1
- 239000012453 solvate Substances 0.000 title 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/72—Nitrogen atoms
- C07D213/73—Unsubstituted amino or imino radicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4412—Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1218640.9A GB201218640D0 (en) | 2012-10-17 | 2012-10-17 | Chemical compounds |
| GB201306881A GB201306881D0 (en) | 2013-04-16 | 2013-04-16 | Chemical compounds |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG10201708166SA true SG10201708166SA (en) | 2017-11-29 |
Family
ID=49488610
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201502515VA SG11201502515VA (en) | 2012-10-17 | 2013-10-15 | Tert-butyl n-[2-{4-[6-amino-5-(2,4-difluorobenzoyl)-2-oxopyridin-1(2h)-yl]-3,5- difluorophenyl}ethyl]-l-alaninate or a salt, hydrate or solvate thereof |
| SG10201708166SA SG10201708166SA (en) | 2012-10-17 | 2013-10-15 | Tert-Butyl N-[2-{4-[6-Amino-5-(2,4-Difluorobenzoyl)-2-Oxopyridin-1(2H)-yl]-3,5-Difluorophenyl}Ethyl]-L-Alaninate Or A Salt, Hydrate Or Solvate Thereof |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201502515VA SG11201502515VA (en) | 2012-10-17 | 2013-10-15 | Tert-butyl n-[2-{4-[6-amino-5-(2,4-difluorobenzoyl)-2-oxopyridin-1(2h)-yl]-3,5- difluorophenyl}ethyl]-l-alaninate or a salt, hydrate or solvate thereof |
Country Status (27)
| Country | Link |
|---|---|
| US (3) | US9388136B2 (en) |
| EP (2) | EP3222616B1 (en) |
| JP (2) | JP6260975B2 (en) |
| KR (1) | KR102164536B1 (en) |
| CN (2) | CN104781235B (en) |
| AU (1) | AU2013333636B2 (en) |
| BR (1) | BR112015008167B1 (en) |
| CA (1) | CA2888928C (en) |
| CY (2) | CY1119080T1 (en) |
| DK (2) | DK3222616T3 (en) |
| ES (2) | ES2635240T3 (en) |
| HK (1) | HK1211028A1 (en) |
| HR (2) | HRP20171320T1 (en) |
| HU (2) | HUE046132T2 (en) |
| IL (2) | IL237863B (en) |
| IN (1) | IN2015DN02721A (en) |
| LT (1) | LT3222616T (en) |
| MX (1) | MX364782B (en) |
| NZ (1) | NZ706717A (en) |
| PL (2) | PL3222616T3 (en) |
| PT (2) | PT3222616T (en) |
| RS (2) | RS59458B1 (en) |
| RU (1) | RU2676329C2 (en) |
| SG (2) | SG11201502515VA (en) |
| SI (2) | SI2909175T1 (en) |
| WO (1) | WO2014060742A1 (en) |
| ZA (1) | ZA201501958B (en) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR112015008167B1 (en) * | 2012-10-17 | 2020-11-17 | Macrophage Pharma Limited | compound, pharmaceutical composition, methods for inhibiting the activity of a map p38 kinase enzyme, for the treatment or prevention of autoimmune or inflammatory disease in an individual, and for the treatment, improvement or reduction of the incidence of cell proliferative disease in an individual, compound use, and, acid |
| GB201713975D0 (en) * | 2017-08-31 | 2017-10-18 | Macrophage Pharma Ltd | Medical use |
Family Cites Families (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU650953B2 (en) | 1991-03-21 | 1994-07-07 | Novartis Ag | Inhaler |
| JP4472349B2 (en) | 2002-02-12 | 2010-06-02 | スミスクライン ビーチャム コーポレーション | Nicotinamide derivatives useful as p38 inhibitors |
| JP2005526068A (en) | 2002-03-14 | 2005-09-02 | バイエル・ヘルスケア・アクチェンゲゼルシャフト | Monocyclic aroylpyridinones as anti-inflammatory agents |
| GB0509223D0 (en) | 2005-05-05 | 2005-06-15 | Chroma Therapeutics Ltd | Enzyme inhibitors |
| GB0509225D0 (en) | 2005-05-05 | 2005-06-15 | Chroma Therapeutics Ltd | Inhibitors of enzymatic activity |
| US20090215800A1 (en) | 2005-05-05 | 2009-08-27 | Chroma Therapeutics Ltd | Enzyme and Receptor Modulation |
| GB0509227D0 (en) | 2005-05-05 | 2005-06-15 | Chroma Therapeutics Ltd | Intracellular enzyme inhibitors |
| GB0510204D0 (en) | 2005-05-19 | 2005-06-22 | Chroma Therapeutics Ltd | Enzyme inhibitors |
| GB0608837D0 (en) | 2006-05-04 | 2006-06-14 | Chroma Therapeutics Ltd | Inhibitors of MAP kinase |
| GB0608823D0 (en) | 2006-05-04 | 2006-06-14 | Chroma Therapeutics Ltd | Inhibitors of P13 kinase |
| GB0608855D0 (en) * | 2006-05-04 | 2006-06-14 | Chroma Therapeutics Ltd | Inhibitors of MAP kinase enzymes |
| DK2013175T5 (en) | 2006-05-04 | 2020-12-21 | Macrophage Pharma Ltd | p38 Map kinase inhibitors |
| GB0608821D0 (en) | 2006-05-04 | 2006-06-14 | Chroma Therapeutics Ltd | DHFR enzyme inhibitors |
| GB0619753D0 (en) | 2006-10-06 | 2006-11-15 | Chroma Therapeutics Ltd | Enzyme inhibitors |
| GB0621203D0 (en) | 2006-10-25 | 2006-12-06 | Chroma Therapeutics Ltd | PLK inhibitors |
| BRPI0718120A2 (en) | 2006-10-25 | 2013-11-12 | Chroma Therapeutics Ltd | PTERIDINE DERIVATIVES AS POLE TYPE KINASE INHIBITORS USEFUL IN CANCER TREATMENT |
| CA2668070A1 (en) | 2006-10-30 | 2008-05-08 | Chroma Therapeutics Ltd. | Hydroxamates as inhibitors of histone deacetylase |
| ES2372707T3 (en) | 2006-11-01 | 2012-01-25 | Chroma Therapeutics Limited | INHIBITORS OF THE IKK-BETA SERINA-TREONINA PROTEIN QUINASA. |
| WO2008053185A1 (en) | 2006-11-01 | 2008-05-08 | Chroma Therapeutics Ltd. | INHIBITORS OF IKK-β SERINE-THREONINE PROTEIN KINASE |
| US20100267774A1 (en) | 2007-11-07 | 2010-10-21 | Chroma Therapeutics Ltd. | P38 map kinase inhibitors |
| GB0803747D0 (en) | 2008-02-29 | 2008-04-09 | Martin | Enzyme and receptor modulation |
| US8778953B2 (en) | 2008-02-29 | 2014-07-15 | Chroma Therapeutics Ltd. | Inhibitors of P38 map kinase |
| BRPI0822522A2 (en) | 2008-04-23 | 2018-06-05 | Chroma Therapeutics Ltd | IKK-BETA SERINE- THREONINE PROTEIN KINASE INHIBITORS |
| GB0807451D0 (en) | 2008-04-24 | 2008-05-28 | Chroma Therapeutics Ltd | Inhibitors of PLK |
| JP2011518817A (en) | 2008-04-26 | 2011-06-30 | クロマ セラピューティクス リミテッド | Substituted thiophenecarboxamides as IKK-β serine-, threonine-protein kinase inhibitors |
| GB0903480D0 (en) | 2009-02-27 | 2009-04-08 | Chroma Therapeutics Ltd | Enzyme Inhibitors |
| GB0907120D0 (en) | 2009-04-24 | 2009-06-03 | Chroma Therapeutics Ltd | Inhibitors of IKK-ß serine-threonine protein kinase |
| GB201009853D0 (en) | 2010-06-11 | 2010-07-21 | Chroma Therapeutics Ltd | HSP90 inhibitors |
| GB201021467D0 (en) | 2010-12-17 | 2011-02-02 | Chroma Therapeutics Ltd | Imaging agents |
| GB201211310D0 (en) | 2012-06-26 | 2012-08-08 | Chroma Therapeutics Ltd | CSF-1R kinase inhibitors |
| BR112015008167B1 (en) * | 2012-10-17 | 2020-11-17 | Macrophage Pharma Limited | compound, pharmaceutical composition, methods for inhibiting the activity of a map p38 kinase enzyme, for the treatment or prevention of autoimmune or inflammatory disease in an individual, and for the treatment, improvement or reduction of the incidence of cell proliferative disease in an individual, compound use, and, acid |
-
2013
- 2013-10-15 BR BR112015008167-3A patent/BR112015008167B1/en not_active IP Right Cessation
- 2013-10-15 PL PL17168533T patent/PL3222616T3/en unknown
- 2013-10-15 ES ES13783363.8T patent/ES2635240T3/en active Active
- 2013-10-15 RU RU2015115213A patent/RU2676329C2/en active
- 2013-10-15 SI SI201330714T patent/SI2909175T1/en unknown
- 2013-10-15 JP JP2015537346A patent/JP6260975B2/en not_active Expired - Fee Related
- 2013-10-15 AU AU2013333636A patent/AU2013333636B2/en not_active Ceased
- 2013-10-15 EP EP17168533.2A patent/EP3222616B1/en active Active
- 2013-10-15 DK DK17168533.2T patent/DK3222616T3/en active
- 2013-10-15 RS RSP20191330 patent/RS59458B1/en unknown
- 2013-10-15 PT PT17168533T patent/PT3222616T/en unknown
- 2013-10-15 PL PL13783363T patent/PL2909175T3/en unknown
- 2013-10-15 LT LTEP17168533.2T patent/LT3222616T/en unknown
- 2013-10-15 DK DK13783363.8T patent/DK2909175T3/en active
- 2013-10-15 IN IN2721DEN2015 patent/IN2015DN02721A/en unknown
- 2013-10-15 MX MX2015004368A patent/MX364782B/en active IP Right Grant
- 2013-10-15 CN CN201380054069.6A patent/CN104781235B/en not_active Expired - Fee Related
- 2013-10-15 SG SG11201502515VA patent/SG11201502515VA/en unknown
- 2013-10-15 ES ES17168533T patent/ES2743768T3/en active Active
- 2013-10-15 HU HUE17168533A patent/HUE046132T2/en unknown
- 2013-10-15 KR KR1020157012809A patent/KR102164536B1/en active IP Right Grant
- 2013-10-15 EP EP13783363.8A patent/EP2909175B1/en active Active
- 2013-10-15 CA CA2888928A patent/CA2888928C/en active Active
- 2013-10-15 US US14/436,404 patent/US9388136B2/en active Active
- 2013-10-15 WO PCT/GB2013/052689 patent/WO2014060742A1/en active Application Filing
- 2013-10-15 HU HUE13783363A patent/HUE035525T2/en unknown
- 2013-10-15 NZ NZ706717A patent/NZ706717A/en not_active IP Right Cessation
- 2013-10-15 PT PT137833638T patent/PT2909175T/en unknown
- 2013-10-15 RS RS20170646A patent/RS56184B1/en unknown
- 2013-10-15 CN CN201610944341.3A patent/CN106496106B/en not_active Expired - Fee Related
- 2013-10-15 SG SG10201708166SA patent/SG10201708166SA/en unknown
- 2013-10-15 SI SI201331557T patent/SI3222616T1/en unknown
-
2015
- 2015-03-20 ZA ZA2015/01958A patent/ZA201501958B/en unknown
- 2015-03-22 IL IL237863A patent/IL237863B/en active IP Right Grant
- 2015-12-01 HK HK15111816.2A patent/HK1211028A1/en not_active IP Right Cessation
-
2016
- 2016-06-15 US US15/183,612 patent/US9896417B2/en active Active
-
2017
- 2017-07-17 CY CY20171100756T patent/CY1119080T1/en unknown
- 2017-08-31 HR HRP20171320TT patent/HRP20171320T1/en unknown
- 2017-10-11 JP JP2017197466A patent/JP6464244B2/en not_active Expired - Fee Related
- 2017-12-25 IL IL256560A patent/IL256560B/en active IP Right Grant
-
2018
- 2018-01-03 US US15/861,586 patent/US10370332B2/en not_active Expired - Fee Related
-
2019
- 2019-09-23 CY CY20191101002T patent/CY1122194T1/en unknown
- 2019-10-15 HR HRP20191874TT patent/HRP20191874T1/en unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| FIC20230031I1 (en) | lvosidenib or a pharmaceutically acceptable salt, tautomer, isotopologue or hydrate thereof | |
| ZA201504197B (en) | N-(substituted)-5-fluoro-4-imino-3-methyl-2-oxo-3,4-dihydropyrimidine-1 (2h)-carboxamides derivatives | |
| PL2589592T3 (en) | Novel nicotinamide derivatives or salts thereof | |
| RS62542B1 (en) | 2-(2,4,5-substituted-anilino)pyrimidine compounds | |
| HK1207072A1 (en) | 3,5-diaminopyrazole kinase inhibitors 35- | |
| HK1214475A1 (en) | N-(substituted)-5-fluoro-4-imino-3-methyl-2-oxo-3,4- dihydropyrimidine-1 (2h)-carboxylate derivatives n-()-5--4--3--2--34--1(2h)- | |
| GB201610846D0 (en) | Methods of authenticating a user for data exchange | |
| ZA201604932B (en) | N1-(3,3,3-trifluoro-2-hydroxo-2-methylpropionyl)-piperidine derivatives as inhibitors of pyruvate dehydrogenase kinase | |
| IL240197B (en) | Method for preparing 1-(4-(4-(3,4-dichloro-2-fluorophenylamino)-7-methoxyquinazolin-6-yloxy)piperidin-1-yl)prop-2-en-1-one | |
| IL256560B (en) | Tert-butyl n-[2-{4-[6-amino-5-(2,4-difluorobenzoyl)-2-oxopyridin-1(2h)-yl]-3,5- difluorophenyl}ethyl]-l-alaninate or a salt, hydrate or solvate thereof | |
| HUE046668T2 (en) | 1,4-dihydropyridine derivatives with hsp modulating activity | |
| EP2863905A4 (en) | Substituted picolinamide kinase inhibitors | |
| HK1211869A1 (en) | A 6-oxo-1,6-dihydro-pyridazine derivative for the use for the treatment of hepatocellular carcinoma (hcc) (hcc) 6--16-- | |
| EP2924028A4 (en) | Trpv-1 receptor antagonist compound derived from 1,3,4-thiadiazole alkylamides and chalcones | |
| GB201222378D0 (en) | Backing-up user data | |
| IL238829A0 (en) | Process for preparing 4-(cyclopropylmethoxy)-n-(3,5-dichloro-1-oxido-4-pyridyl)-5-methoxypyridine-2-carboxamide | |
| TWM433267U (en) | Tool set with pivotally changed head | |
| AU336302S (en) | 'SATIN' Ruche sleeve tunic |